# Grace Therapeutics, Inc.: filings

GRCE · Nasdaq · CIK 1444192 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Mar 31

Pages: [Overview](/companies/grce.md) · [Financials](/companies/grce/financials.md) · [Filings](/companies/grce/filings.md) · [Insiders](/companies/grce/insiders.md)

## Reports and events: 370 filings

Newest first, by EDGAR acceptance time (Eastern). Filter with ?form= one of: `periodic`, `8-K`, `10-K`, `10-Q`, `4`, `proxy`, `13dg`, `all`, or any form this company filed (6-K 230, 8-K 95, 4 66, 3 23, 10-Q 19, EFFECT 14, SCHEDULE 13G/A 12, CORRESP 11, UPLOAD 9, 10-K 7, 20-F 6, 424B3 6, 425 6, DEFA14A 6, F-1/A 6, 424B5 5, D 5, DEF 14A 5, POS AM 5, S-3 4, S-8 4, SC 13G 4, SC 13G/A 4, 4/A 3, S-8 POS 3, 10-Q/A 2, CERTNAS 2, F-3 2, F-X 2, S-4 2, S-4/A 2, SC 13D/A 2, SCHEDULE 13G 2, SUPPL 2, 10-K/A 1, 3/A 1, 40-F 1, 40FR12G 1, 40FR12G/A 1, 424B4 1, 8-A12B 1, 8-K/A 1, F-1 1, F-10 1, FWP 1, PRE 14A 1, SC 13D 1).

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-18 | 16:06 ET | [8-K](/filings/0001140361-26-037114.md) | 5.07 Shareholder vote results | 0001140361-26-037114 |
| 2026-08-13 | 08:01 ET | [8-K](/filings/0001140361-26-032644.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001140361-26-032644 |
| 2026-08-13 | 07:30 ET | [10-Q](/filings/0001140361-26-032632.md) | Quarterly report, period 2026-06-30 | 0001140361-26-032632 |
| 2026-08-06 | 16:06 ET | [8-K](/filings/0001140361-26-031671.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-26-031671 |
| 2026-07-28 | 16:29 ET | [DEF 14A](/filings/0001140361-26-029889.md) | Proxy statement, period 2026-09-17 | 0001140361-26-029889 |
| 2026-07-28 | 07:16 ET | [8-K](/filings/0001140361-26-029837.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-26-029837 |
| 2026-06-18 | 08:15 ET | [8-K](/filings/0001140361-26-025669.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-26-025669 |
| 2026-06-18 | 08:01 ET | [8-K](/filings/0001140361-26-025667.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001140361-26-025667 |
| 2026-06-18 | 07:31 ET | [10-K](/filings/0001140361-26-025662.md) | Annual report, period 2026-03-31 | 0001140361-26-025662 |
| 2026-06-05 | 16:09 ET | [8-K](/filings/0001140361-26-024269.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001140361-26-024269 |
| 2026-04-27 | 07:08 ET | [8-K](/filings/0001140361-26-016834.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-26-016834 |
| 2026-04-23 | 14:36 ET | [8-K](/filings/0001140361-26-016324.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-26-016324 |
| 2026-02-12 | 08:01 ET | [8-K](/filings/0001140361-26-004927.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001140361-26-004927 |
| 2026-02-12 | 07:31 ET | [10-Q](/filings/0001140361-26-004924.md) | Quarterly report, period 2025-12-31 | 0001140361-26-004924 |
| 2026-01-12 | 17:00 ET | [8-K](/filings/0001140361-26-000995.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001140361-26-000995 |
| 2025-11-17 | 16:22 ET | [10-Q/A](/filings/0001140361-25-042491.md) | Quarterly report, amended, period 2025-09-30 | 0001140361-25-042491 |
| 2025-11-13 | 08:01 ET | [8-K](/filings/0001140361-25-041807.md) | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-25-041807 |
| 2025-11-13 | 07:31 ET | [10-Q](/filings/0001140361-25-041804.md) | Quarterly report, period 2025-09-30 | 0001140361-25-041804 |
| 2025-10-23 | 08:09 ET | [8-K](/filings/0001140361-25-039020.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-25-039020 |
| 2025-09-18 | 08:43 ET | [8-K](/filings/0001140361-25-035337.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-25-035337 |
| 2025-09-12 | 16:13 ET | [8-K](/filings/0001140361-25-034845.md) | 5.07 Shareholder vote results | 0001140361-25-034845 |
| 2025-08-27 | 08:08 ET | [8-K](/filings/0001140361-25-032847.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-25-032847 |
| 2025-08-12 | 08:00 ET | [8-K](/filings/0001140361-25-030400.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001140361-25-030400 |
| 2025-08-12 | 07:31 ET | [10-Q](/filings/0001140361-25-030398.md) | Quarterly report, period 2025-06-30 | 0001140361-25-030398 |
| 2025-07-28 | 07:00 ET | [DEF 14A](/filings/0001140361-25-027456.md) | Proxy statement, period 2025-09-12 | 0001140361-25-027456 |
| 2025-06-25 | 08:19 ET | [8-K](/filings/0001140361-25-023557.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-25-023557 |
| 2025-06-23 | 08:00 ET | [8-K](/filings/0001140361-25-023261.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001140361-25-023261 |
| 2025-06-23 | 07:43 ET | [10-K](/filings/0001140361-25-023259.md) | Annual report, period 2025-03-31 | 0001140361-25-023259 |
| 2025-04-09 | 08:00 ET | [8-K](/filings/0001140361-25-012944.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-25-012944 |
| 2025-03-03 | 08:00 ET | [8-K](/filings/0001140361-25-006659.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-25-006659 |
| 2025-02-19 | 20:25 ET | [10-Q/A](/filings/0001140361-25-005051.md) | Quarterly report, amended, period 2024-12-31 | 0001140361-25-005051 |
| 2025-02-13 | 08:00 ET | [8-K](/filings/0001140361-25-004157.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001140361-25-004157 |
| 2025-02-13 | 07:30 ET | [10-Q](/filings/0001140361-25-004153.md) | Quarterly report, period 2024-12-31 | 0001140361-25-004153 |
| 2025-02-10 | 08:11 ET | [8-K](/filings/0001140361-25-003645.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-25-003645 |
| 2024-11-13 | 08:00 ET | [8-K](/filings/0001140361-24-046314.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001140361-24-046314 |
| 2024-11-13 | 07:30 ET | [10-Q](/filings/0001140361-24-046312.md) | Quarterly report, period 2024-09-30 | 0001140361-24-046312 |
| 2024-10-28 | 08:22 ET | [8-K](/filings/0001140361-24-044363.md) | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001140361-24-044363 |
| 2024-10-25 | 08:13 ET | [8-K](/filings/0001140361-24-044212.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-24-044212 |
| 2024-10-07 | 16:13 ET | [8-K](/filings/0001140361-24-042968.md) | 1.01 Entry into a material agreement; 3.03 Change to security holders’ rights; 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001140361-24-042968 |
| 2024-09-30 | 16:31 ET | [8-K](/filings/0001140361-24-042352.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001140361-24-042352 |
| 2024-09-25 | 08:00 ET | [8-K](/filings/0001140361-24-041832.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-24-041832 |
| 2024-08-16 | 16:05 ET | [8-K](/filings/0000950170-24-098049.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0000950170-24-098049 |
| 2024-08-09 | 08:00 ET | [8-K](/filings/0000950170-24-094359.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-094359 |
| 2024-08-09 | 07:30 ET | [10-Q](/filings/0000950170-24-094348.md) | Quarterly report, period 2024-06-30 | 0000950170-24-094348 |
| 2024-06-27 | 16:10 ET | [8-K](/filings/0000950170-24-078447.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-24-078447 |
| 2024-06-21 | 08:00 ET | [8-K](/filings/0000950170-24-075880.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-075880 |
| 2024-06-21 | 07:30 ET | [10-K](/filings/0000950170-24-075875.md) | Annual report, period 2024-03-31 | 0000950170-24-075875 |
| 2024-04-01 | 08:00 ET | [8-K](/filings/0000950170-24-038882.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-24-038882 |
| 2024-02-12 | 08:00 ET | [8-K](/filings/0000950170-24-013568.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-013568 |
| 2024-02-12 | 07:30 ET | [10-Q](/filings/0000950170-24-013566.md) | Quarterly report, period 2023-12-31 | 0000950170-24-013566 |

Page 1 of 8. [Older](/companies/grce/filings.md?page=2)
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 26, 2026, 18:07 ET. No prices; not investment advice.